By Stewart Eisenhart, Emergo Group
Contributed Blogs
CareFusion may be weighing 2 very different deals
Smarter strategic moves bode well for Wright Medical
There’s a saying in the markets that there’s always a bull market somewhere. Along similar lines, it’s almost always possible to find areas of growth in otherwise stagnant med-tech markets. While the overall performance of the orthopedic market has been pretty uninspiring of late, the extremities sub-sectors (upper and lower extremities) have been notable exceptions.
A Father’s Day remembrance
by Charles Ornstein, ProPublica
This story was co-published with The Washington Post.
When conduct becomes a crime
By: John Roth
In my last post, I explained how FDA’s Office of Criminal Investigation (OCI) works when a small portion of the industry fails to adequately respond to regulatory action. For Abbott Laboratories and Amgen, the price for regulatory malfeasance was high: $1.4 billion – yes, billion – paid in criminal and civil penalties to the United States.
Can C.R. Bard use a windfall to reignite growth?
CEO Insight: Allergan’s David Pyott on the federal Sunshine Act
By David Pyott
MedWatch: Improving on 20 Years of Excellence
By Margaret A. Hamburg, M.D.
This week FDA is proudly commemorating the 20th anniversary of MedWatch, a program which collects and reviews reports from health professionals and consumers about possible problems with drugs, medical devices and other products regulated by FDA.
FDA and MDMA: Moving Forward Together
Edwards Lifesciences comes back down to earth – hard
Taiwan’s medical device industry poised for 7% growth
By Stewart Eisenhart, Emergo Group
A new study by the Taiwan Industry of Economic Affairs’ Industry and Technology Intelligence Services (ITIS) projects the country’s medical device industry to grow to $2.71 billion in 2013, an increase of more than seven percent.